Mihir Maheshkumar Shah MD FACS, FSSO (He/Him)
Hepatobiliary Surgery, Pancreas, Surgical Oncology (Other than Breast), Minimally Invasive Surgery
Chief of Surgical Oncology, MedStar Washington Hospital Center Associate Medical Director of Surgical Oncology Research, MedStar Health
Join to view full profile
110 Irving St NWWashington, DC 20010
Phone+1 202-877-4599
Fax+1 202-877-0448
Dr. Shah is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Mihir M. Shah, MD, is a surgical oncologist based in Washington, DC, with interest in hepatobiliary surgery, pancreas, gastrointestinal surgical oncology (excluding breast), and minimally invasive surgery. He has advanced training from Emory University School of Medicine and Rutgers Health/Robert Wood Johnson Medical School, and he completed surgical residencies at the Cleveland Clinic Foundation. His research has been published in leading journals such as Nature, Annals of Surgical Oncology and Journal of American College of Surgeons. He is also the Principal Investigator for a clinical trial on neoadjuvant treatment for pancreatic cancer.
Education & Training
Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Complex General Surgical Oncology, 2016 - 2018
Emory University School of MedicineFellowship, Advanced GI Minimally Invasive Surgery, 2015 - 2016
Cleveland Clinic FoundationResidency, Surgery, 2011 - 2015
Mercy Catholic Medical CenterResidency, Surgery, 2010 - 2011
University of SeychellesClass of 2009
Certifications & Licensure
DC State Medical License 2025 - 2028
MD State Medical License 2025 - 2027
GA State Medical License 2014 - 2026
NJ State Medical License 2016 - 2019
OH State Medical License 2011 - 2016
PA State Medical License 2010 - 2011
American Board of Surgery Surgery- American Board of Surgery Complex General Surgical Oncology
Clinical Trials
- Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer Start of enrollment: 2024 Aug 06
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 11 citationsCompetency, Proficiency, and Mastery: Learning Curves for Robotic Distal Pancreatectomy at 16 International Expert Centers.Philip C Müller, Christoph Kuemmerli, Adrian T Billeter, Baiyong Shen, Jiabin Jin
Annals of Surgery. 2026-07-01 - ASO Visual Abstract: Optimal Timing of Adjuvant Therapy for Patients with Poorly Differentiated Pancreatic Adenocarcinoma.Mihir M Shah, Parit T Mavani, Subir Goyal, David A Kooby, Juan M Sarmiento
Annals of Surgical Oncology. 2026-05-01 - Optimal Timing of Adjuvant Therapy in Patients with Poorly Differentiated Pancreatic Adenocarcinoma.Mihir M Shah, Parit T Mavani, Subir Goyal, David A Kooby, Juan M Sarmiento
Annals of Surgical Oncology. 2026-05-01
Journal Articles
- Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer...Mihir M Shah, Darren R Carpizo, Miral S Grandhi, Russell C Langan, Journal of The American College of Surgeons
- Cocaine induced Gastric IschemiaGupta A, Chang J, Shah MM, Journal of International Radiology and Radiation Therapy, 1/1/2018
- Adjuvant Therapeutic Strategies for Resectable Pancreatic AdenocarcinomaYegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, Jabbour SK, Annals of Pancreatic Cancer, 1/1/2018
Books/Book Chapters
Abstracts/Posters
- Subcategorizing T1 Pancreatic Cancer Predicts Survival: An Analysis of the National Cancer Database.Shah MM, NeMoyer RE, Greco SH, Chen C, Moore DF, Grandhi MS, Kennedy TJ, Javidian P, Jabbour SK, August DA, Carpizo DR, Society of Surgical Oncology Annual Cancer Symposium, Chicago, IL, 1/1/2018
- Comparison of Perioperative Chemotherapy vs. Postoperative Chemoradiation Therapy for Distal Gastric Cancer: An Analysis of the National Cancer Database.Shah MM, NeMoyer RE, Greco SH, Lin Y, Grandhi MS, Carpizo DR, Javidian P, Jabbour SK, August DA, Libutti SK, Kennedy TJ, Society of Surgical Oncology Annual Cancer Symposium, Chicago, IL, 1/1/2018
- Outcomes of Patients with Gastric Adenocarcinoma with Peritoneal Metastases undergoing Hyperthermic Intraperitoneal Chemotherapy: An Analysis of the National Cancer Da...Shah MM, NeMoyer RE, Lin Y, Grandhi MS, Carpizo DR, Javidian P, Jabbour SK, August DA, Libutti SK, Alexander HR, Kennedy TJ, The 13th International Symposium on Regional Cancer Therapies, Jacksonville, FL, 1/1/2018
Lectures
- Fascial Closure - Traditional vs. RealityRutgers Robert Wood Johnson Medical School - 1/14/2018
- Surgery Boot Camp for Medical Students (Lecture & Lab)Rutgers Robert Wood Johnson Medical School - 1/6/2018
- Comparison of Perioperative Chemotherapy vs. Postoperative Chemoradiation Therapy for Adenocarcinoma of the Gastric Cardia: An Analysis of the National Cancer Database.Washington, DC - 1/2/2018
Authored Content
- Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer DatabaseOctober 2018
- Reconstruction Options for Pancreaticoduodenectomy in Patients with Prior Roux-en-Y Gastric BypassJune 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: